β-1,4-Gal-T1 Inhibitors

β-1,4-Gal-T1 inhibitors, as listed above, are primarily compounds that indirectly affect the enzyme's activity by modulating glycosylation pathways or related cellular processes. β-1,4-Gal-T1 is responsible for transferring galactose to nascent glycoconjugates, playing a key role in cell surface expression and signaling. The main approach to indirectly inhibiting β-1,4-Gal-T1 involves interfering with substrate availability or processing. Compounds like 2-Deoxy-D-galactose act as analogs of galactose and can compete with natural substrates, potentially inhibiting the activity of β-1,4-Gal-T1. Inhibitors of various glycosidases, such as Kifunensine, Swainsonine, Castanospermine, Deoxynojirimycin, and NB-DNJ, affect the processing of glycoproteins in the endoplasmic reticulum (ER) and Golgi apparatus, which could indirectly impact β-1,4-Gal-T1.

Other compounds target the initial steps of glycosylation or the synthesis of glycoconjugates. Tunicamycin, for example, inhibits N-linked glycosylation, a fundamental step in glycoprotein synthesis, which could subsequently affect β-1,4-Gal-T1 activity. PDMP and Miglustat inhibit glycosphingolipid synthesis, a process linked to the function of β-1,4-Gal-T1. Additionally, disruption of Golgi structure and function with agents like Brefeldin A can have a broad impact on glycosylation processes, including those mediated by β-1,4-Gal-T1.